Format

Send to

Choose Destination
Clin Lymphoma Myeloma. 2008 Jun;8(3):171-5. doi: 10.3816/CLM.2008.n.021.

Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma.

Author information

1
Department of Hematology, University Hospital of Ioannina, Greece. benetatosleon@yahoo.com

Abstract

BACKGROUND:

Methylation represents the most studied epigenetic modification and results in the silencing of genes involved in various processes such as differentiation and cell-cycle regulation. MEG3 represents an imprinted gene maternally expressed in humans that encodes a nontranslated product. In this survey, we studied the methylation status of the specific gene in multiple myeloma (MM).

PATIENTS AND METHODS:

Twenty-one patients with MM (17 with immunoglobulin [Ig] G, 3 with IgA, and 1 with IgM) were evaluated using methylation-specific polymerase chain reaction (after DNA bisulphite modification).

RESULTS:

Promoter hypermethylation was observed in 12 (57.14%) bone marrow samples and in 9 of 14 (64.28%) available peripheral blood samples. A correlation with disease stage was also observed and also with the disease subtype (IgG, 64.7%; IgA, 0; IgM, 100%).

CONCLUSION:

We conclude that promoter hypermethylation of the differentially methylated region of the MEG3 imprinted gene is observed in patients with MM.

PMID:
18650181
DOI:
10.3816/CLM.2008.n.021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center